Bevacizumab is a VEGF inhibitor indicated for the treatment of colorectal cancer, non-small cell lung cancer, glioblastoma, cervical cancer, and renal cell carcinoma [27]. This evidence concerns the gene VEGFA and cervical carcinoma.